Dyspareunia is a common symptom of vulvar and vaginal atrophy, which often occurs in women who have already undergone menopause.
Intrarosa, developed by Queben, Canada-based Endoceutics, is a once-daily vaginal insert.
The product represents the first FDA-approved treatment to contain the active ingredient prasterone, according to a press release on the agency’s website.
More articles on supply chain:
Gavis Pharma earns FDA approval for generic painkiller
Amazon sues sellers for allegedly bogus products
Study: Generic heart drugs vary widely in price, limit access to uninsured patients
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
